Creating a New Word To Bring about Next-gen Antibiotics

Antibiotics are powerful medicines that are used to fight against bacterial infections and diseases. These are specifically used to treat infections caused by bacteria such as, Staph., Strep., or E. coli. Antibiotics either kill the bacteria (bactericidal) or restrictit from reproducing and growing (bacteriostatic). The antibiotics do not work against any viral infection. Some of the common infections treated with antibiotics are, conjunctivitis, skin or soft tissue infection, upper respiratory tract infection, bronchitis, streptococcal pharyngitis (strep throat), and among others.

A generic medicine is a copy of a branded drug that is no longer under patent. Generic versions are introduced in the market with an aim to offer cost-efficient drugs and increase the reach of these drugs to people belonging to different economic classes. Generic versions are popular due to their availability and affordability.

Download PDF Copy Here https://bit.ly/2SoJX0M

For instance, according to a study published on the NCBI in 2018, the average brand name prescription price was almost 4-times the average generic price. Additionally, the companies are also focusing on the development of generic versions with an aim to offer antibiotics at minimal costs. For instance, in June 2018, Lupin launched generic Tobramycin inhalation solution in the US market. Further, encouragement from government authorities is also projected to drive the production of generic antibiotics, which would eventually drive the growth of the antibiotics market during the forecast period. For instance, in February 2019, the US Food and Drug Administration (US FDA) announced approval for commercialization of generic medicines manufactured by Indian drug companies in the US.

A large number of players have been focusing on new drug development and clinical trials. Prominent biotechnology companies are entering into strategic alliances, which has helped them make considerable investments in drug discovery. Pharmaceutical companies are developing analogues of existing antibiotic classes based on innovative approaches to fight bacterial infections.

Pfizer, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Abbott, GlaxoSmithKine Plc, Sanofi, Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company, and Astellas Pharma are among the leading companies operating in the antibiotics market.

The companies are focused towards the adoption of organic strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in May 2017, Pfizer's launched new antibiotic for multidrug resistant (MDR) infections Zavicefta in the UK and Germany, its first lauch was in EU markets.

Source: The Insight Partners